10x Genomics (TXG) Form 4: Officer Sells 8,283 Shares to Cover Taxes

10x Genomics, Inc. reported an insider stock transaction by a senior executive.

Rhea-AI Filing Summary

10x Genomics, Inc. reported an insider stock transaction by a senior executive. On 11/24/2025, a reporting person who serves as both a director and as President and Chief Scientific Officer sold 8,283 shares of Class A common stock of 10x Genomics, Inc. (TXG) at a price of $18.9983 per share. According to the explanation provided, the shares were sold to cover tax withholding obligations that arose when restricted stock units vested, meaning the transaction was tied to equity compensation rather than a discretionary open-market sale.

After this transaction, the reporting person beneficially owned 432,605 shares of Class A common stock in direct form. The Form 4 was filed for a single reporting person and does not report any derivative securities activity.

Insider Trade Summary

Net Seller: 8,283 shares

Net Sell 1 txn

Insider Hindson Benjamin J.

Role See Remarks

Sold 8,283 shs ($157K)

Type	Security	Shares	Price	Value
Sale	Class A Common Stock	8,283	$18.9983	$157K

Holdings After Transaction: Class A Common Stock — 432,605 shares (Direct)

Footnotes (1)

1. F1. The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did 10x Genomics (TXG) report in this Form 4?

The Form 4 reports that a senior executive and director of 10x Genomics, Inc. sold 8,283 shares of Class A common stock on 11/24/2025.

At what price were the 10x Genomics (TXG) shares sold in the reported transaction?

The 8,283 shares of 10x Genomics Class A common stock were sold at a price of $18.9983 per share.

Why did the 10x Genomics (TXG) insider sell 8,283 shares?

The filing states that the shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units.

How many 10x Genomics (TXG) shares does the insider own after this transaction?

Following the reported sale, the insider beneficially owns 432,605 shares of 10x Genomics Class A common stock in direct ownership.

Does this 10x Genomics (TXG) Form 4 report any derivative securities?

The Form 4 includes a table for derivative securities, but no derivative transactions are reported in the provided content.

What is the role of the reporting person in 10x Genomics (TXG)?

The reporting person is identified as both a director and an officer, serving as President and Chief Scientific Officer of 10x Genomics, Inc.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/25/2025 - 05:24 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hindson Benjamin J.

(Last) (First) (Middle)

10X GENOMICS, INC.

6230 STONERIDGE MALL ROAD

(Street)

PLEASANTON CA 94588

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
10x Genomics, Inc. [ TXG ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
11/24/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	11/24/2025		S(1)		8,283	D	$18.9983	432,605	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units.

Remarks:

President and Chief Scientific Officer

	/s/ Eric S. Whitaker, as Attorney-in-Fact for Benjamin J. Hindson	11/25/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.